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Abstract 
 
Background 
The Brief Intervention for Weight Loss Trial enrolled 1882 consecutively attending primary care 
patients who were obese and participants were randomised to physicians opportunistically 
endorsing, offering, and facilitating a referral to a weight loss programme (support) or 
recommending weight loss (advice).  After one year, the support group lost 1.4kg more (95%CI 0.9 to 
2.0): 2.4 kg versus 1.0 kg. We use a cohort simulation to predict effects on disease incidence, quality 
of life, and healthcare costs over 20 years.  
 
Methods 
Randomly sampling from the trial population, we created a virtual cohort of 20 million adults and 
assigned baseline morbidity.  We applied the weight loss observed in the trial and assumed weight 
regain over four years.  Using epidemiological data, we assigned the incidence of 12 weight-related 
diseases depending on baseline disease status, age, gender, body mass index.  From a healthcare 
perspective, we calculated the quality adjusted life years (QALYs) accruing and calculated the 
incremental difference between trial arms in costs expended in delivering the intervention and 
healthcare costs accruing.  We discounted future costs and benefits at 1.5% over 20 years. 
 
Results 
Compared with advice, the support intervention reduced the cumulative incidence of weight-related 
disease by 722/100,000 people, 0.33% of all weight-related disease. The incremental cost of support 
over advice was £2.01million/100,000.  However, the support intervention reduced health service 
costs by £5.86 million/100,000 leading to a net saving of £3.85 million/100,000.  The support 
intervention produced 992 QALYs/100,000 people relative to advice.  
 
Conclusions 
A brief intervention in which physicians opportunistically endorse, offer, and facilitate a referral to a 
behavioural weight management service to patients with a BMI of at least 30kg/m2 reduces 
healthcare costs and improves health more than advising weight loss. 
  
Introduction 
Screening and brief intervention for obesity in primary care is effective. In the first 
randomised trial of such an intervention, called BWeL (Brief intervention for Weight Loss) 
ISRCTN26563137,1, 2 we screened consecutive patients attending 137 primary care 
physicians in England for obesity, defined as a BMI of at least 25kg/m2 for people of Asian 
ethnicity or 30kg/m2 for people of other ethnicities together with a raised body fat 
percentage for age and gender.  Eighty-three percent of people who had a BMI at or above 
these limits agreed to participate and 1882 participants were enrolled. In the support 
intervention, physicians advised patients that the best way to lose weight was to attend one 
of two well-known UK commercial weight management programmes which are available as 
a 12-week group programme paid for by the English NHS and offered them a referral to the 
group.  These were Slimming World and Rosemary Conley.  If the patient agreed to this, 
s/he was given a specific appointment before leaving the practice.  Of the 940 participants 
in this arm, 77% of the patients agreed to the referral and 40% attended.  For the 942 
participants in the advice arm, physicians advised the patient their health would benefit 
from weight loss.  Patients welcomed the intervention; one in 500 thought the intervention 
inappropriate and unhelpful, while more than four in five thought it appropriate and 
helpful.  The mean weight loss among all people offered the intervention at 12 months was 
2.4kg in the support condition and 1.0kg in the advice condition, an adjusted difference 
(95% confidence interval) 1.43 (0.89 to 1.97).  Twenty-five percent of the support condition 
lost 5% of their body weight, compared with 14% of the control, an odds ratio 2.11 (1.67 to 
2.68).  
 
It is uncertain whether this is a cost-effective intervention.  Firstly, although the intervention 
is of modest cost, it yielded modest weight loss.  Furthermore, while losing weight reduces 
the risk of diabetes and other obesity-related diseases,3 most people who lose weight regain 
it.4 The incidence of obesity-related disease is the same after lost weight is regained as it 
would have been without weight loss, even though the cumulative incidence is lower in the 
long-term.5  It therefore remains uncertain whether providing a brief intervention of this 
kind is a cost-effective intervention, which we investigate here by computing the 
incremental cost-effectiveness ratio for the support intervention relative to the advice 
intervention from the perspective of the healthcare system. 
 Methods 
Model set-up 
We modelled the cost-effectiveness of a one-off delivery of both the support and advice 
intervention in the trial. To do so we created virtual populations of 20 million people by 
randomly sampling with replacement from the adult population enrolled in the BWeL trial.  
We applied a BMI growth equation to the BMI of cohort members, simulated using a Monte 
Carlo process. The data on BMI change were projected forward based on past trends in BMI 
for age and gender-specific groups in the English population taken from the Health Survey 
for England from 2004 to 2014. The individuals in the virtual cohort model were followed in 
annual cycles for 20 years or until death from 2015 to 2035.  In each year, an individual 
could develop obesity-related disease, recover from it, or die from it.  The probabilities of 
these outcomes depended on age, sex, and BMI with the data for these probabilities 
derived from systematic reviews of the literature.  If an individual developed disease, we 
modelled the QALY decrement that ensued and the healthcare costs, with the data again 
derived from the literature.  The modelling used the UK Health Forum (UKHF) 
Microsimulation Model. This model was developed for the Foresight Tackling Obesities 
Report and has been used subsequently to predict the prevalence of obesity in various 
countries or specific cohorts, and its consequences on health outcomes, and the economic 
costs that these entail in the population.6-10  
 
In the first year, we applied the mean weight loss observed in each trial arm to eligible 
individuals in each virtual cohort. We then assumed that in the second and subsequent four 
years, any weight lost was regained linearly back to where their starting BMI percentile 
would have been if the person was following natural trends for their age and gender.  These 
trends were derived from the Health Survey for England.4  Thus individuals where there is 
average weight gain over time (typically younger groups) returned to a weight higher than 
baseline and those where there is average weight loss (typically older groups) returned to a 
point lower than baseline. After the fifth year of the simulation, individuals in both scenarios 
progressed along their BMI percentile, following national trends in BMI for their age and 
gender. We therefore assumed that weight trajectories diverged for five years and that all 
lost weight was regained and that the intervention did not recur. 
 
Intervention effectiveness 
We applied the weight loss of each intervention to the cohort representing the participants 
in each arm of the trial in year 1 of the modelling (Appendix Table 1 and Figure 1). In the 
intervention group, the effect of the intervention depended on whether or not a patient 
attended or did not attend the weight loss programme when it was offered and this was 
allocated at random in the model.  Those that did attend (40% of the trial arm) lost a mean 
of 4.7kg and those that did not attend lost a mean of 0.7kg.1  In the advice group, we 
applied a uniform effect to each member of the cohort, representative of the mean weight 
loss in the advice arm of the BWeL trial (1.0kg). 
 
Figure 1 The two scenarios for modelling the effectiveness of interventions 
 
 
Data on obesity-related disease 
In the second stage of modelling, we assessed the incidence of 12 obesity-related diseases 
in the cohort. These were breast cancer, cardiovascular disease, colorectal cancer, type 2 
diabetes mellitus, endometrial cancer, hypertension, knee osteoarthritis, oesophageal 
cancer, ovarian cancer, pancreatic cancer, renal cancer, and stroke. At baseline, we applied 
baseline prevalence based on a person’s age, gender, and BMI using data from the literature 
(Appendix Table 2).  In subsequent years, the model calculated an individual’s transition 
probability using a Monte Carlo process of developing disease based on their age, sex, 
current disease state, medical history and risk factor (BMI). The incidence was assumed to 
depend solely on current BMI, which, at least for diabetes, appears to be the case.5  For the 
stochastic transitions used in the microsimulation, this probability was derived from an 
application-generated random number to determine if the transition takes place for a 
particular individual.  The data on the incidence of disease and the relation of that to BMI 
was derived from published sources which in turn were derived from periodically updated 
systematic searching and appraisal (Table 2 Appendix).  In addition, in subsequent turns of 
the model, the disease could remit, continue, or lead to death and those data too were 
derived from epidemiological sources and applied stochastically to cohort members.  We 
summarised the incidence of obesity-related disease in each arm of the model using 
cumulative incidence over the 20-year period.  This represents the total number of new 
cases of weight-related disease occurring in a population during this time.  As people are at 
risk of all diseases and because these typically co-occur e.g. many people develop both 
diabetes and hypertension, this is different from the number of people with a disease. 
 
Health economics data 
We assigned a QALY value to each of the disease states (Table 2- Appendix) using data on 
EQ-5D, as recommended by the English healthcare decision making body, NICE. The 
majority of the EQ-5D measures were obtained from Sullivan et al 11 and otherwise from 
searching of the literature.  Following English guidance (NICE), we discounted future 
benefits at 1.5%.12 
 
Data on direct costs only were obtained from the NHS England programme budgeting cost 
database 2012-2013. Expenditure figures included only healthcare costs incurred by the 
NHS reflecting that the analysis was undertaken from the healthcare perspective.13 The 
intervention costs were derived from the trial (Appendix Table 3).  The costs included the 
costs of a person weighing themselves before the consultation (the scale depreciation cost 
along with minimal staff supervision time), the time of the physician in delivering the brief 
intervention, which applied in both arms.  In the support arm, the additional costs were the 
time of the physician’s receptionist booking an appointment at the weight management 
programme, depending on the participants response.  The largest cost was that of the 
weight loss programme itself (£49.50), which was the NHS contracting cost applicable in 
2015, the base year of the modelling, if the participant chose to take up this offer.  The costs 
of healthcare for incident disease modelled comprised primary care costs (staff and 
prescriptions); secondary care (inpatient: elective, non-elective, outpatient and other 
secondary care); urgent care/emergency care costs (ambulance and accident and 
emergency); community care costs; and cost of care provided in other settings: In the NHS 
budget cost database, only the total healthcare expenditure of diabetes, as opposed to type 
2 diabetes was available. Based on epidemiological data, we assumed that 90% of diabetes 
prevalence and associated costs were attributable to type 2 diabetes.14 There were no UK 
data on hypertension costs so data from the Netherlands were used.  We followed a 
standard approach by discounting future costs and benefits at 1.5% per year, as 
recommended for economic outputs by NICE.12   
 
Incremental cost-effectiveness of the support intervention relative to advice 
The difference in costs and health outcomes between the two brief interventions was used 
to calculate the incremental cost-effectiveness ratio (ICER) of the support intervention 
compared with the advice arm: the difference in costs (net difference between healthcare 
and intervention costs incurred) divided by the difference in health outcomes (quality 
adjusted life years (QALY) gained). The ICER was compared to a threshold, which is the 
“price” society is willing to pay for an extra unit of health “output”, in this case a QALY, 
which helps determine whether the intervention tested is good value for money.15  We used 
NICE’s threshold of £20,000/QALY. 
 Results 
Epidemiological results of the long-term cost effectiveness of the BWeL study 
In the advice arm, by 2035, the cumulative incidence of obesity-related disease was 
predicted to be 219,249 cases per 100,000 i.e. on average people developed two obesity-
related conditions over the 20 years.  The largest contributors were pre-diabetes (64,470), 
diabetes (34,824), and hypertension (79,764), with 14,472 cases of heart disease and 10,115 
cases of stroke.  In the support arm, the cumulative total incidence was 218,707 cases per 
100,000 people, a reduction in cumulative incidence of obesity-related disease of 0.33%.  
The predicted number of cases (% reduction) of prediabetes was 64,534 (0.36%), diabetes 
34,675 (0.43%), hypertension 79,476 (0.36%), heart disease 14,450 (0.15%), and stroke 
10,016 (0.09%) per 100,000 (Figures 2 and 3).  
 
 
Figure 2 - Total cumulative incidence of diseases (cases/100,000 (95%CI)) avoided by year 
 
  
Figure 3 - Cumulative Incidence avoided (cases per 100,000 population) for active relative to support scenarios in the UK by 2035  
 
 
Health economics results of the long-term cost effectiveness of the BWeL study 
The support intervention cost between £1.95 and £51.45 per person, depending on the 
patient’s response, while the advice intervention cost £1.95 (Appendix Table 3).  The 
incremental cost of the support intervention over advice was £20.10/person or £2.01 
million/100,000 population.  The main additional cost was the cost of the weight loss 
programme.  However, it reduced health service costs by 5.86 million/100,000 leading to a 
net saving of £3.85 million/100,000. 
 
By 2035, the reduced incidence of disease from the support intervention produced an 
additional 992 QALYs/100,000 people relative to advice.  This resulted in a dominant result 
for the ICER: more effective and at lower cost.  This result varied over the 20 years.  In the 
third year, the intervention was cost-effective by NICE standards and cost-saving by the 
ninth year (Figure 4). 
 
Figure 4. The ICER (£/QALY) for support versus advice over 20 years 
 
Discussion 
Relative to advice to lose weight, a physician’s opportunistic offer of referral to group-based 
community weight loss support programme was more effective at reducing the incidence of 
obesity-related disease.  Although it was costlier in the short-term, it was cost-effective 
from the third year after its implementation and cost-saving from year nine and over an 
entire 20-year period, while yielding an additional 992 QALYs/100,000 people. 
 
The main strength of this study relates to the underpinning data from a trial and the model 
we used to model the long-term health impact.  The randomised design of the trial, 
delivered at population-level rather than to a selected group of motivated participants 
makes it possible to estimate the population level impact of physician-led interventions. The 
model addresses the question relevant to policy: how the initial costs of offering treatment 
for obesity are balanced in relation to the disease prevented. The model was developed for 
the UK Foresight Report and has updated since then.16-18 
 
We randomised people to a control intervention which was physician advice to lose weight 
to improve health, and this could be a limitation.  In clinical practice, it is rare to make 
opportunistic interventions on weight,19, 20 and so advice to lose weight does not represent 
usual care.  The cost of delivering the brief advice intervention would not ordinarily have 
been incurred and thus our analysis underestimates the cost difference between usual 
current care and the active intervention in the trial, thus overestimating the cost-
effectiveness.  However, the costs of the advice intervention were modest at £0.2 
million/100,000 and even removing this cost entirely would not change the findings that the 
support intervention was cost-saving.  Moreover, it is plausible that physician advice itself 
spurred action in some participants.  On average, participants in this arm lost 1kg, about 
700g more than epidemiological evidence might suggest.21  If this were so, this may have 
underestimated the ICER because it underestimated the weight gain difference and hence 
health benefits of weight loss.  Neither issue seems likely to change the conclusion that the 
support intervention, involving endorsing, offering, and facilitating a referral to a modestly 
priced group-based weight management service is cost-saving and improves health to a 
greater extent than either simple advice or usual care, namely no intervention.  A further 
limitation is that the results are based on a trial analysis and therefore apply directly only in 
the UK where physicians have access to referral to a programme that is modestly priced and 
effective.  However, if physicians only have access to more costly weight loss programmes, 
then the cost saving would diminish, albeit the cost of the weight loss programme would 
have to be three times greater for the support arm to be cost neutral over 20 years.  A final 
issue is that the microsimulation model is not currently able to conduct sensitivity analyses.   
 
The analysis was conducted from the healthcare perspective, including only costs and 
benefits occurring in healthcare.  A societal perspective would have included costs to the 
participants from attending the weight loss programme, for example, and the opportunity 
cost of the time spent doing so, which is considerable.  We also excluded other costs that 
are arguably relevant including some weight-related diseases due to lack of data to model 
the impact and indirect and social care costs of the weight-related diseases in the model.  
Weight-related diseases are major risk factors for dependency in old age.22  However, we 
excluded costs that might arise from treatment and care for people with non-weight-related 
disease, which is likely to increase in incidence simply as a result of a longer life following 
weight loss23. which may reduce or eliminate the cost-savings.  However, there is a debate 
about whether these additional costs should be included or not.24, 25  A lifetime societal 
perspective may have given a different estimate of the costs and benefits.  However, our 
analysis was conducted in the same manner as other health economic analyses used to 
inform healthcare spending decisions, but the total net financial impact of this (or other 
healthcare) intervention on society remains unknown. 
 
Another limitation is that the trial followed up participants at three months and one year, 
during which time participants regained weight.  Their experience was typical of trials in 
general and we assumed that they would regain all lost weight over the next four years.4  If 
weight regain were either more rapid or slower than this or if all weight lost was not 
regained, as occurred in the Diabetes Prevention Program,5 the cost-effectiveness would 
change.  Our assumptions were based on a systematic review that estimated the rate of 
weight regain and found no evidence that the means by which weight loss occurred affected 
the rate of regain.26  Those few trials that have followed people for up to five years or longer 
have not observed that all weight lost has been regained.5, 27  Thus, as with most modelling, 
the assumptions are critical to the outcomes obtained.  Validating this model would be 
difficult.  In this study, all participants were recruited opportunistically and very briefly to 
conceal the nature of the intervention.  By follow-up, many had forgotten being enrolled in 
a study and follow-up over 20 years, as would be required to directly estimate the costs of 
healthcare and assess quality of life would be difficult and, even in a trial of nearly 1800 
people, would be subject to occasional high cost episodes of healthcare that can affect 
health-economic assessments, as we have observed previously.10  A final issue is that this 
economic analysis could not include a probabilistic sensitivity analysis.  There are a large 
number of parameters in the model and a single run of the model takes several days.  
Running a sensitivity analysis would require a super computer. 
 The BWeL trial was the first trial to examine the effectiveness of physician-delivered 
opportunistic brief interventions.  This is therefore the first cost-effectiveness evaluation of 
this kind of population-level intervention for weight-loss.  However, although the central 
feature of BWeL was the physician-delivered brief intervention offered to a population not 
seeking support, 1 the biggest cost element and the element that delivered the weight loss 
was the 12-week commercial weight management programme to which primary care 
physicians referred the participants. This kind of service is available for physicians to refer to 
in many parts of England, and there is evidence that this is an effective programme.28, 29  The 
most recent such evaluation suggested that, compared with a self-help intervention (for 
which there is evidence of effectiveness),30 the 12-week programme was cost-saving.31  Our 
findings extend this evaluation because they included a delivery mechanism that has 
potentially a very high reach, certainly much higher than waiting for patients to ask for 
support, which is what happens in usual care.  The large majority of people visit a primary 
care physician annually, making several visits a year.32, 33  Physicians could feasibly give a 30-
second intervention sufficiently often to greatly expand the reach of effective weight loss 
programmes to have a real population impact and it would be valuable to assess this. That 
said, the same model was used in both cost-effectiveness evaluations.  Although we have 
tried to be explicit about some assumptions in the model, it is possible that different models 
would produce different outputs and replicating these results in a different model would be 
helpful.  A final issue is that this intervention, a brief opportunistic intervention by a 
physician, if implemented by policy, would be implemented recurrently.  For example, 
English general practitioners have a requirement to update smoking status and provide 
support in how to quit to their patients that smoke every two years.  Here we modelled the 
cost-effectiveness of the intervention as delivered only once, replicating a within-trial cost-
effectiveness evaluation, but the impact of both recurrent costs and the impact on 
recurrent benefits remain unknown.  Further modelling could usefully explore a range of 
scenarios to understand the possible impact of rollout of this programme. 
Conclusions 
A brief intervention where primary care physicians opportunistically endorse, offer, and 
facilitate a referral to weight management to consecutively attending patients who have a 
BMI of at least 30kg/m2 was cost-saving over a 20-year time horizon while improving health.  
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Appendix  
Table 1 Inputs for the model from the BWeL trial for BMI drops and costs. 
 Baseline Advice Support (whole 
group) 
Support (accept and 
attend programme) 
Support (accept but 
do not attend 
programme) 
Support (decline 
referral) 
Weight loss mean (SD) 
in kg at 1 year 
No change 1.04 (5.50) 2.43 (6.49) 4.91(7.92) 0.75 (4.59) 0.75 (4.59) 
BMI loss mean (SD) 
(kg/m2) at 1 year 
No change 0.36 (2.06) 0.85 (2.31) 1.74 (2.83) 0.25 (1.63) 0.25 (1.63) 
 
  
Table 2 – Source of disease data inputs  
Disease Incidence Prevalence Mortality Survival Relative Risk  Utility Direct costs* 
CHD Smolina et al 2012. 
Corrected data on 
incidence and mortality in 
2013 34 
BHF, Cardiovascular 
Disease Statistics 2014 35 
ONS, Deaths Registrations 
Summary Statistics, 
England and Wales, 2014 36 
Computed from prevalence 
and mortality 
World Obesity Federation 
(DYNAMO project) 37 
Laires et al. 2015 38 NHS 2012-13 programme 
budgeting data 13 
Stroke BHF, stroke statistics 2009 
39 
BHF, Cardiovascular 
Disease Statistics 2014 35 
ONS, Deaths Registrations 
Summary Statistics, 
England and Wales, 2014 36 
Computed from prevalence 
and mortality 
World Obesity Federation 
(DYNAMO project) 37 
Rivero-Arias et al. 2010 -40 NHS 2012-13 programme 
budgeting data 13 
Hypertension Derived from prevalence Health Survey for England 
2012  41 
non terminal non terminal World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 Netherlands data as proxy 
Polder et al, 2002 42 
Diabetes Personal communication 
Dr. Craig Currie at Cardiff 
University  
International Diabetes 
Federation, 2014 43 
non terminal non terminal Derived from PREVEND 
data (Jaccard 2015 et al. 
Manuscript in preparation. 
 
Sullivan et al. 2011 11 IDF atlas 2014 43 
Knee Osteoarthritis Derived from prevalence Arthritis UK 
Musculoskeletal calculator 
44 
non terminal non terminal Zheng et al (2015) 45 
 
Conner-Spady et al. 2015 46 Oxford Economics Report 
2010 47 
Breast cancer CRUK, 2013  Statistics by 
cancer type 48 
NA CRUK Mortality by cancer 
type49 
ONS Cancer Survival in 
England: adults diagnosed 
between 2009 and 2013 
and followed up to 2014 50 
& ONS Cancer Survival in 
England: 10 year survival 
rates adults diagnosed 
between 2010-2011 and 
followed up to 2012 51 
World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 NHS 2012-13 programme 
budgeting data 13 
Colorectal cancer NA World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 
Endometrial cancer NA World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 
Oesophageal 
cancer 
NA World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 
Ovarian cancer NA Aune et al. 2015 52 Sullivan et al. 2011 11 
Pancreatic cancer NA World Cancer Research 
Fund, 200753 
Romanus et al. 2012 54 
Renal cancer NA World Obesity Federation 
(DYNAMO project) 37 
Sullivan et al. 2011 11 
* Cost data were collected from the NHS England budgeting cost database 2012-2013. NHS England recommended to us not to use more recent data because it might underestimate the 
costs, as not all costs from clinical commissioning groups are included. Some assumptions were needed: 90% of the costs of diabetes care were assumed to be due to type II diabetes.  
Missing data on the costs of hypertension care in the UK were obtained from data from the Netherlands.  All future costs were discounted at 1.5% per year in line with recommendations 
from NICE.  
Table 3 – Intervention costs (£) of modelled intervention scenarios* 
  Advice intervention Support intervention (accept 
and attend weight 
management programme) 
Support intervention (accept 
and do not attend weight 
management programme) 
Support intervention 
(decline  referral) 
GP time 1.45 1.45 1.45 1.45 
Receptionist time 0 0.27 0.27 0 
Weight loss 
programme 
0 £49.50 0 0 
Scale + staff cost 0.50 0.50 0.50 0.50 
Total (£)  1.95 51.45 2.22 1.95 
* derived from Unit Costs of Health and Social Care 2015 Compiled by Lesley Curtis and Amanda Burns55 
 
 
 
